| Stochastic response surface methods (SRSMs) for uncertainty propagation: application to environmental and biological systems SS Isukapalli, A Roy, PG Georgopoulos Risk analysis 18 (3), 351-363, 1998 | 518 | 1998 |
| Accumulation of chlorpyrifos on residential surfaces and toys accessible to children. S Gurunathan, M Robson, N Freeman, B Buckley, A Roy, R Meyer, ... Environmental health perspectives 106 (1), 9-16, 1998 | 352 | 1998 |
| Measurement of children's exposure to pesticides: analysis of urinary metabolite levels in a probability-based sample. JL Adgate, DB Barr, CA Clayton, LE Eberly, NC Freeman, PJ Lioy, ... Environmental health perspectives 109 (6), 583-590, 2001 | 230 | 2001 |
| Model‐based population pharmacokinetic analysis of nivolumab in patients with solid tumors G Bajaj, X Wang, S Agrawal, M Gupta, A Roy, Y Feng CPT: pharmacometrics & systems pharmacology 6 (1), 58-66, 2017 | 226 | 2017 |
| Innovative approaches for designing and analyzing adaptive dose-ranging trials B Bornkamp, F Bretz, A Dmitrienko, G Enas, B Gaydos, CH Hsu, F König, ... Journal of biopharmaceutical statistics 17 (6), 965-995, 2007 | 218 | 2007 |
| Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors X Zhao, S Suryawanshi, M Hruska, Y Feng, X Wang, J Shen, HE Vezina, ... Annals of Oncology 28 (8), 2002-2008, 2017 | 187 | 2017 |
| Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy S Agrawal, Y Feng, A Roy, G Kollia, B Lestini Journal for immunotherapy of cancer 4 (1), 1-11, 2016 | 183 | 2016 |
| Exposure–response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma Y Feng, A Roy, E Masson, TT Chen, R Humphrey, JS Weber Clinical Cancer Research 19 (14), 3977-3986, 2013 | 175 | 2013 |
| Quantitative analysis of children's microactivity patterns: The Minnesota Children's Pesticide Exposure Study NCG Freeman, M Jimenez, KJ Reed, S Gurunathan, RD Edwards, A Roy, ... Journal of Exposure Science & Environmental Epidemiology 11 (6), 501-509, 2001 | 151 | 2001 |
| Efficient sensitivity/uncertainty analysis using the combined stochastic response surface method and automated differentiation: application to environmental and biological systems SS Isukapalli, A Roy, PG Georgopoulos Risk Analysis 20 (5), 591-602, 2000 | 128 | 2000 |
| Identification of non–small cell lung cancer sensitive to systemic cancer therapies using radiomics L Dercle, M Fronheiser, L Lu, S Du, W Hayes, DK Leung, A Roy, ... Clinical Cancer Research 26 (9), 2151-2162, 2020 | 124 | 2020 |
| Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study X Wang, A Roy, A Hochhaus, HM Kantarjian, TT Chen, NP Shah Clinical pharmacology: advances and applications 5, 85, 2013 | 111 | 2013 |
| A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration Y Wang, A Roy, L Sun, CE Lau Drug Metabolism and Disposition 27 (8), 855-859, 1999 | 103 | 1999 |
| Model‐based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma Y Feng, E Masson, D Dai, SM Parker, D Berman, A Roy British journal of clinical pharmacology 78 (1), 106-117, 2014 | 92 | 2014 |
| Nivolumab exposure–response analyses of efficacy and safety in previously treated squamous or nonsquamous non–small cell lung cancer Y Feng, X Wang, G Bajaj, S Agrawal, A Bello, B Lestini, FG Finckenstein, ... Clinical Cancer Research 23 (18), 5394-5405, 2017 | 90 | 2017 |
| Quantitative characterization of the exposure–response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma X Wang, Y Feng, G Bajaj, M Gupta, S Agrawal, A Yang, JS Park, B Lestini, ... CPT: pharmacometrics & systems pharmacology 6 (1), 40-48, 2017 | 82 | 2017 |
| Uncertainty reduction and characterization for complex environmental fate and transport models: An empirical Bayesian framework incorporating the stochastic response surface method S Balakrishnan, A Roy, MG Ierapetritou, GP Flach, PG Georgopoulos Water Resources Research 39 (12), 2003 | 74 | 2003 |
| Biomarkers of environmental benzene exposure. C Weisel, R Yu, A Roy, P Georgopoulos Environmental health perspectives 104 (suppl 6), 1141-1146, 1996 | 67 | 1996 |
| Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors S Agrawal, P Statkevich, G Bajaj, Y Feng, S Saeger, DD Desai, JS Park, ... The Journal of Clinical Pharmacology 57 (3), 394-400, 2017 | 64 | 2017 |
| Population pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation B Cirincione, K Kowalski, J Nielsen, A Roy, N Thanneer, W Byon, R Boyd, ... CPT: pharmacometrics & systems pharmacology 7 (11), 728-738, 2018 | 62 | 2018 |
